P448 Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn’s disease – an update from the TISKids study

Vuijk, S.(1)*;Jongsma, M.(1);Cozijnsen, M.(1);van Pieterson, M.(1);de Meij, T.(2);Norbruis, O.(3);Groeneweg, M.(4);Wolters, V.(5);van Wering, H.(6);Hojsak, I.(7);Kolho, K.L.(8);Hummel, T.(9);Stapelbroek, J.(10);van der Feen, C.(11);van Rheenen, P.(12);van Wijk, M.(2);Teklenburg, S.(3);Escher, J.(1);de Ridder, L.(1);

(1)Erasmus Medical Center / Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(2)Emma Children’s Hospital- Amsterdam UMC- VU University, Department of Paediatric Gastroenterology, Amsterdam, The Netherlands;(3)Isala Hospital, Department of Paediatric Gastroenterology, Zwolle, The Netherlands;(4)Maasstad Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(5)Utrecht Medical Center/ Wilhelmina Children’s Hospital, Department of Paediatric Gastroenterology, Utrecht, The Netherlands;(6)Amphia Hospital, Department of Paediatric Gastroenterology, Breda, The Netherlands;(7)Children’s Hospital Zagreb, Department of Paediatric Gastroenterology, Zagreb, Croatia;(8)University of Helsinki, Department of Pediatric Gastroenterology, Helsinki, Finland;(9)Medical Spectrum Twente, Department of Paediatric Gastroenterology, Enschede, The Netherlands;(10)Catharina Hospital, Department of Paediatric Gastroenterology, Eindhoven, The Netherlands;(11)Jeroen Bosch Hospital, Department of Paediatric Gastroenterology, ‘s Hertogenbosch, The Netherlands;(12)University of Groningen- University Medical Center, Department of Paediatric Gastroenterology, Groningen, The Netherlands;